Infant Bacterial Therapeutics Issues Corrected Notice for 2026 AGM in Stockholm

The latest announcement is out from Infant Bacterial Therapeutics AB ( ($SE:IBT.B) ).

Infant Bacterial Therapeutics AB has issued a corrected notice for its Annual General Meeting, to be held on May 7, 2026 in Stockholm, after the earlier version contained a technical error in the numbering of the proposed agenda. Shareholders must be registered by April 28 and notify participation by April 30, including any proxy arrangements and registration of nominee-held shares, to exercise their voting rights at the meeting.

The agenda includes standard governance items such as approval of financial statements, discharge from liability for the board and CEO, and decisions on board and auditor elections and fees. The Nomination Committee proposes re-election of the current five board members, re-appointment of Peter Rothschild as chairman, selection of an authorized audit firm, as well as board fees that remain unchanged, alongside board proposals on executive remuneration guidelines, a share issuance authorization, and a new employee stock option program, which could influence future capital structure and staff incentives.

The most recent analyst rating on ($SE:IBT.B) stock is a Hold with a SEK48.00 price target. To see the full list of analyst forecasts on Infant Bacterial Therapeutics AB stock, see the SE:IBT.B Stock Forecast page.

More about Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB is a Stockholm-based biopharmaceutical company focused on developing microbiome-based therapies for infants. The company operates in the pharmaceutical and biotechnology industry, targeting serious diseases in premature and infants through innovative bacterial therapeutic products and related clinical research activities.

Average Trading Volume: 6,446

Technical Sentiment Signal: Sell

Current Market Cap: SEK677.6M

See more data about IBT.B stock on TipRanks’ Stock Analysis page.